CD8+ T-cells in Atherosclerosis: mechanistic studies revealing a protective role in the plaque microenvironment
Duijn, J. van

Citation
Duijn, J. van. (2020, April 28). *CD8+ T-cells in Atherosclerosis: mechanistic studies revealing a protective role in the plaque microenvironment*. Retrieved from https://hdl.handle.net/1887/136335

Version:	Publisher's Version
License:	Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from:	https://hdl.handle.net/1887/136335

Note: To cite this publication please use the final published version (if applicable).

Cover Page

The handle http://hdl.handle.net/1887/136335 holds various files of this Leiden University dissertation.

Author: Duijn, J. van
Title: CD8+ T-cells in Atherosclerosis: mechanistic studies revealing a protective role in the plaque microenvironment
Issue Date: 2020-04-28

Tc17 CD8$^+$ T-cells accumulate in murine atherosclerotic lesions and modulate local inflammatory responses

Janine van Duijn[a], Naomi Benne[a], Romain J.T. Leboux[a], Marieke E. van Ooijen[a], Nicky Kruit[a], Amanda C. Foks[a], Wim Jiskoot[a], Ilze Bot[a], Johan Kuiper[a], Bram Slütter[a]

[a] Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands

Manuscript submitted

ABSTRACT

Aims CD8$^+$ T-cells can differentiate into subpopulations that are characterized by a specific cytokine profile, such as the Tc17 population that produces IL-17. The role of this CD8$^+$ T-cell subset in atherosclerosis remains elusive. In this study, we therefore investigated the contribution of Tc17 cells to the development of atherosclerosis.

Methods and Results Flow cytometry analysis of atherosclerotic lesions from apoE$^{-/-}$ mice revealed a pronounced increase in RORγt+CD8$^+$ T-cells compared to the spleen, indicating a lesion-specific increase in Tc17 cells. To study whether and how the Tc17 subset affects atherosclerosis, we performed an adoptive transfer of Tc17 cells or undifferentiated Tc0 cells into CD8$^{-/-}$LDLr$^{-/-}$ mice fed a Western-type diet. Using flow cytometry, we showed that Tc17 cells retained a high level of IL-17A production *in vivo*. Moreover, Tc17 cells produced lower levels of IFN-γ than their Tc0 counterparts. Analysis of the aortic root revealed a decrease in atherosclerotic lesion size in the Tc17-treated mice compared to Tc0-treated mice, associated with a decrease in plaque macrophage content as well as a reduction in inflammatory CD4$^+$ Th1 cells.

Conclusion These findings demonstrate a lesion-localized increase in Tc17 cells in an atherosclerotic mouse model. Adoptive transfer of these cells into CD8$^{-/-}$LDLr$^{-/-}$ mice reduces lesion size compared to the transfer of Tc0 cells, suggesting a protective role for Tc17 cells in atherosclerosis.

1. Introduction

Atherosclerosis, the most frequent underlying pathology of cardiovascular disease, is characterized by both the buildup of cholesterol as well as chronic inflammation within the wall of large- and medium-sized arteries. T-cells are observed in both early and advanced atherosclerotic lesions [1] and have been shown to contribute to lesion initiation and progression [2–4]. Different subsets of $CD4^+$ helper-T cells have been extensively described and studied in the context of atherosclerosis [5]. A pro-atherogenic function is ascribed to the interferon-γ (IFN-γ)-producing T helper 1 (Th1) subset [6, 7], whereas the interleukin (IL)-10-producing regulatory T cells (Tregs) are atheroprotective [8, 9]. The role of the Th2 subset, characterized by the production of IL-4 and IL-5, is more controversial. Whereas the signature Th2 cytokines IL-4, IL-5, and IL-33 are reported to inhibit atherosclerosis development [2, 10, 11], reduced Th2 responses and IL-4 deficiency were also reported to decrease lesion formation [12–14], suggesting a pro-atherogenic role for Th2 cells as well. Finally, the IL-17-producing Th17 subset is known to drive autoimmunity and atherogenesis via activation of the endothelium, increasing pro-inflammatory cytokine production, and contributing to macrophage recruitment [15–17]. In contrast, loss of suppressor of cytokine signaling (SOCS) 3 in T cells, resulting in increased IL-17 and IL-10 production, reduces atherosclerotic lesion development [18]. This effect is mediated via the induction of an anti-inflammatory macrophage phenotype and a reduction in vascular inflammation. Interestingly, treatment with recombinant IL-17 resulted in reduced expression of vascular cell adhesion molecule-1 (VCAM-1) as well as reduced T-cell infiltration in the lesions, suggesting the aforementioned atheroprotective effects of SOCS3 knockout are at least in part mediated via IL-17.

In a similar vein to their $CD4^+$ T-cell counterparts, $CD8^+$ T-cells can be categorized into subsets based on their cytokine production. Upon activation of $CD8^+$ T-cells, cytokines released by antigen-presenting cells (APCs) can influence the differentiation of the $CD8^+$ T-cells into different subsets. The cytokines IL-2 and IL-12 drive $CD8^+$ T-cells towards a Tc1 phenotype through the induction of the transcription factor T-box–containing protein expressed in T cells (T-bet) [19, 20]. Tc1 cells are known for their cytotoxic function and expression of effector molecules, such as granzymes, perforin, IFN-γ and TNF-α [21, 22]. These cells confer protection against intracellular infections [23, 24] as well as cancer [25]. Alternatively, the release of IL-4 by the APCs polarizes $CD8^+$ T-cells towards a Tc2 phenotype [26]. These cells express the transcription factor GATA3 and are characterized by the production of the cytokines IL-4, IL-5 and IL-13 [21, 26–28]. This cell type is known to propagate allergic reactions and contribute to autoimmune disorders, such as arthritis [29–31]. Finally, exposure to the cytokines IL-6, IL-21, and TGF-β drives $CD8^+$ T-cells to differentiate towards a Tc17 phenotype, by inducing the expression of the transcription factors RAR-related orphan nuclear receptor γt (RORγt) and interferon regulatory factor 4 [32, 33]. Tc17 cells are characterized by their production of IL-17 and have been shown to play a pro-inflammatory role in several autoimmune disorders, such as multiple sclerosis, diabetes and arthritis [21, 33–35].

The roles of CD8$^+$ T-cell subsets in atherosclerosis remain largely unexplored, although there are some studies suggesting that these cells may be involved. Tc1 cells have been implicated in atherogenesis, as IFN-γ-producing CD8$^+$ T-cells potentiated atherosclerosis development in apolipoprotein E deficient (apoE$^{-/-}$) mice [36]. Additionally, IFN-γ produced by CD8$^+$ T-cells was shown to contribute to monopoiesis during early lesion development in low-density lipoprotein receptor-deficient (LDLr$^{-/-}$) mice [37]. Moreover, apoE$^{-/-}$ mice deficient in E3-ligase CBL-B showed an increase in IFN-γ and granzyme B-producing CD8$^+$ T-cells, resulting in enhanced macrophage killing and atherosclerosis [38]. Finally, an increase in IL-17-producing CD8$^+$ T-cells in the circulation of humans has been associated with a higher incidence of myocardial infarction [39], hinting at a role for Tc17 cells in cardiovascular disease. However, direct evidence showing a causal relation between Tc17 cells and atherosclerosis is lacking.

Here, we systematically investigated the presence of different CD8$^+$ T-cell subsets in a murine model of atherosclerosis and observed an increase in the number of Tc17 cells within the lesions. We show that undifferentiated CD8$^+$ T-cells switch to a Tc1 phenotype when transferred into LDLr$^{-/-}$ mice on a Western-type diet (WTD). CD8$^+$ T-cells that are polarized towards Tc17 cells however, produced lower levels of IFN-γ upon adoptive transfer and showed a reduced atherogenicity compared to their Tc1 counterparts.

2. Methods

2.1. Mice

C57Bl/6, CD8$^{-/-}$, LDLr$^{-/-}$ and apoE$^{-/-}$ mice were purchased from Jackson Laboratory (Bar Harbor, Maine, USA) and bred in-house. CD8$^{-/-}$ mice were crossed with LDLr$^{-/-}$ mice to obtain CD8$^{-/-}$LDLr$^{-/-}$ mice in-house, after which genotypes were verified by PCR. The mice were kept under standard laboratory conditions and food and water were provided *ad libitum*. For the development of advanced atherosclerotic lesions in apoE$^{-/-}$ mice, mice were kept on a chow diet for 39-49 weeks before analysis of CD8$^+$ T-cell phenotypes in the lesion. Upon sacrifice, mice were subcutaneously anesthetized with a lethal dose of ketamine (40 $mg\,ml^{-1}$), sedazine (8 $mg\,ml^{-1}$) and atropine (0.1 $mg\,ml^{-1}$). All animal work was performed in compliance with the Dutch government guidelines and the Directive 2010/63/EU of the European Parliament. Experiments were approved by the Ethics Committee for Animal Experiments of Leiden University.

2.2. Cell preparation and flow cytometry

Mice were sacrificed as described above and blood, spleens, and aortas were harvested after in situ perfusion with phosphate-buffered saline (PBS, pH 7.4, Lonza). White blood cells were obtained by lysing blood samples two times for 2 min with lysis buffer (0.15 M NH_4Cl, 1 mM $KHCO_3$, 0.1 mM Na_2EDTA; pH 7.3). Single-cell suspensions of

spleens were obtained by using a 70 μm cell strainer (Greiner Bio-One). Splenocytes were lysed for 1 min with lysis buffer to obtain white blood cells. Aortas were cleaned of perivascular fat, cut into small pieces, and digested by incubation with a digestion mix (collagenase I 450 $U\,mL^{-1}$, collagenase XI 250 $U\,mL^{-1}$, DNAse 120 $U\,mL^{-1}$, and hyaluronidase 120 $U\,mL^{-1}$; all Sigma-Aldrich) for 30 min at 37 °C while shaking, and subsequently strained over a 70 μm strainer. Cells were stained with the appropriate antibodies (Table S1). For intracellular staining, cells were fixed and permeabilized by using an intracellular staining kit (eBioscience) according to the manufacturer's protocol. To detect cytokine production, cells were stimulated for 3.5 hours with phorbol 12-myristate 13-acetate (PMA, 50 $ng\,ml^{-1}$, Sigma-Aldrich) and ionomycin (500 $ng\,ml^{-1}$, Sigma-Aldrich) in the presence of brefeldin A (ThermoScientific) in complete RPMI 1640 medium containing 25 mM HEPES (Lonza) supplemented with 5% foetal bovine serum (Greiner), 60 μM β-mercaptoethanol (Sigma), 100 $U\,mL^{-1}$ mix of penicillin/streptomycin (Lonza), 1% non-essential amino acids (NEAA; Gibco), 1% sodium pyruvate (Sigma), and 2% L-glutamine (Lonza) at 37 °C and 5% CO_2. Flow cytometry analyses were performed on a Beckman Coulter Cytoflex S and FlowJo software (Treestar).

2.3. *In vitro* culture of Tc0 and Tc17 cells

Spleens, mesenteric lymph nodes, and iliac lymph nodes were isolated from C57Bl/6 mice after cervical dislocation. $CD8^+$ T-cells were isolated by using a negative selection magnetic $CD8^+$ T-cell isolation kit (Milteny Biotec) according to the manufacturer's protocol. 0.3×10^6 cells were plated per well in a 96-well plate in a total volume of 200 μL complete RPMI (as stated above). In order to obtain undifferentiated Tc0 cells, the medium was supplemented with 20 $U\,mL^{-1}$ IL-2 (Peprotech), 0.5 $ng\,ml^{-1}$ IL-7 (Peprotech), 0.5 $\mu g\,ml^{-1}$ soluble anti-CD3 (ThermoScientific), 0.5 μg ml soluble anti-CD28 (ThermoScientific) and 10 $\mu g\,ml^{-1}$ anti-IFN-γ (BioXcell). For Tc17 differentiation, the medium was supplemented with 20 $U\,mL^{-1}$ IL-2 (Peprotech), 0.5 $ng\,ml^{-1}$ IL-7 (Peprotech), 20 $ng\,ml^{-1}$ IL-6 (Peprotech), 5 $ng\,ml^{-1}$ TGF-β (BioLegend), 20 $ng\,ml^{-1}$ IL-1β (Peprotech), 20 $ng\,ml^{-1}$ IL-23 (R&D systems), 0.5 $\mu g\,ml^{-1}$ soluble anti-CD3 (ThermoScientific), 0.5 $\mu g\,ml^{-1}$ soluble anti-CD28 (ThermoScientific), 10 $\mu g\,ml^{-1}$ anti-IL-4 (BioXcell) and 10 $\mu g\,ml^{-1}$ anti-IFN-γ (BioXcell). The cells were incubated for two days at 37 °C and 5% CO_2, after which the medium was refreshed with the same cytokine stimulations, but without anti-CD3 and anti-CD28. The cells were incubated for one more day before analysis by flow cytometry or adoptive transfer.

2.4. Adoptive transfer

Blood samples of 100 μL were drawn via the tail vein in EDTA-containing tubes (Sarstedt) from 18 $CD8^{-/-}LDLr^{-/-}$ mice between 8 and 14 weeks of age. Total cholesterol levels were assessed by using an enzymatic colorimetric assay (Roche Diagnostics). The mice were randomized into two groups based on age, weight, and plasma cholesterol levels. From the start of the experiment, mice were fed a Western-type diet (WTD) containing 0.25% cholesterol and 15% cocoa butter (Special Diet Services, Witham, Essex,

UK) for 6 weeks. Every week, mice received intravenous injections of matched numbers of between 8.8×10^5 and 2.3×10^6 Tc0 or Tc17 cells, depending on the amount obtained during isolation (on average 1.7×10^6 per injection). During the experiment, transfer efficiency was monitored by drawing blood after 2 and 4 injections of $CD8^+$ T-cells, 5 days after the mice received the last injection. The mice were sacrificed one week after the sixth injection as described above, and organs were isolated as described in Section 2.2.

2.5. Histological analysis

All hearts were embedded in optimal cutting temperature (O.C.T.) compound (Sakura) and horizontally sectioned towards the aortic axis and the aortic arch. Upon reaching of the aortic root, defined by the trivalve leaflets, 10 µm sections were collected. Lesion size analysis was performed on cryosections of the aortic root lesion stained with Oil-red O and hematoxylin (Sigma-Aldrich). Sirius Red staining (Sigma-Aldrich) was performed on corresponding sections to determine collagen content, and Masson's Trichrome staining (Sigma-Aldrich) to determine the necrotic area. Plaque macrophages were stained immunohistochemically by using a rat anti-mouse Monocytes/Macrophages antibody (MOMA, 1:1000, AbD Serotec) as a primary antibody, biotinylated rabbit anti-rat IgG (1:100; Vector) as a secondary antibody, and Vectastain ABC horseradish peroxidase in combination with ImmPACT Nova Red for visualization (Vector). Plaques were stained for VCAM-1 by using purified rat anti-mouse CD106 (1:100, BD Biosciences) as a primary antibody, biotinylated rabbit anti-rat IgG (1:200, Vector) as a secondary antibody and Vectastain ABC horseradish peroxidase in combination with Immpact Nova Red for visualization (Vector). The average plaque size (in μm^2) was calculated from five sequential sections. For all other analyses, three subsequent sections displaying the highest plaque content per mouse were analyzed. All microscopic analyses were performed on a Leica DM-RE microscope using Leica QWin software and were blinded for independent analysis. The relative amount of collagen, macrophages, and necrosis in the atherosclerotic lesions was quantified by dividing the area stained positive for collagen, MOMA or that displaying necrosis by the total lesion surface area, and calculated as a percentage.

2.6. Statistical analysis

The data are presented as individual dot plots with bars denoting the mean, and the number of animals in each group is stated in the text. Data were tested for normal distribution by using a Shapiro-Wilk normality test and analyzed by using a two-tailed Student's *t*-test, Mann–Whitney test, one-way or two-way ANOVA, as appropriate. Statistical analysis was performed using Prism (GraphPad). Probability values of $P < 0.05$ were considered significant.

3. Results

3.1. Increased expression of RORγt by CD8$^+$ T-cells derived from advanced murine atherosclerotic lesions

We investigated the presence of the different CD8$^+$ T-cell subsets in the atherosclerotic lesions of apoE$^{-/-}$ mice with advanced atherosclerosis using flow cytometry. We focused on the difference in phenotype between CD8$^+$ T-cells derived from the aortic lesions and their counterparts in the spleen, as these cells can locally affect the lesion development and composition. We observed a significant decrease in the percentage of CD8$^+$ T-cells that produce IFN-γ within the lesions compared to their counterparts in the spleen (11.7% vs 39.3%, Fig. 1A). This is in line with our previous research, showing a reduced number of cytokine-producing CD8$^+$ T-cells in the lesions of these mice, probably due to the immunosuppressive effects of increased CD39-expression on these cells [40]. We were unable to detect any IL-4 secretion by aortic CD8$^+$ T-cells, whereas we did detect low levels of this cytokine in the splenic CD8$^+$ T-cells (Fig. 1B). Conversely, we observed no production of IL-5 by splenic CD8$^+$ T-cells, whereas there was a low expression of this cytokine in their aortic counterparts (Fig. 1C). Finally, we observed only very low expression levels of IL-17A in the CD8$^+$ T-cells derived from both sites, with no significant differences between the different sites (Fig. 1D). Therefore, we looked into the expression of the key transcription factors associated with the different Tc subsets in the lesions of these mice: T-bet, GATA3, and RORγt for Tc1, Tc2, and Tc17 cells, respectively. Interestingly, we observed a significant 45-fold increase in the percentage of CD8$^+$ T-cells that are positive for RORγt (Fig. 1G), as well as a 19-fold increase in the percentage of GATA3-expressing CD8$^+$ T-cells in the aorta compared to the spleen (Fig. 1F), whereas the percentage of T-bet-expressing CD8$^+$ T-cells showed a 3-fold decrease (Fig. 1E). Of note, we only observed IFN-γ production by the T-bet positive CD8$^+$ T-cells in the aorta, but not by the RORγt or GATA3-expressing CD8$^+$ T-cells (Fig. S1), confirming functionally distinct lineages. As there was such a pronounced increase in the RORγt-expressing lesional CD8$^+$ T-cells, we set out to further explore the role of Tc17 cells in atherosclerosis.

5

3.2. *In vitro* characterization of Tc0 and Tc17 cells

To evaluate the role of Tc17 cells in atherosclerotic lesion development, we decided to perform an adoptive transfer of Tc17 cells into CD8$^{-/-}$LDLr$^{-/-}$ mice. First, we cultured Tc0 and Tc17 cells *in vitro*, based on previously published protocols [33, 41, 42]. CD8$^+$ T-cells were isolated from wild-type mice and activated by using anti-CD3 and anti-CD28 antibodies. Undifferentiated control CD8$^+$ T-cells (Tc0) were cultured for three days in medium supplemented with IL-2, IL-7, and anti-IFN-γ. Tc17 cells were differentiated for three days in medium supplemented with IL-2, IL-7, IL-6, IL-1β, TGF-β, IL-23, anti-IL-4, and anti-IFN-γ. Flow cytometry analysis revealed that our approach led to a robust Tc17 phenotype, with a 19-fold increase in the percentage of cells positive for IL-17A in the Tc17 cells compared to the Tc0 cells (24.8% vs 1.3%, Fig. 2A), associated with a 5-fold increase in RORγt-expressing cells (13.2% vs. 2.7%, Fig. 2B),



Figure 1: Murine atherosclerotic lesions display an increased expression of the Tc17-associated transcription factor RORγt as well as the Tc2-associated transcription factor GATA3 within the CD8$^+$ T-cell compartment compared to the spleen. Flow cytometric analysis of IFN-γ^+ (A), IL-4$^+$ (B), IL-5$^+$ (C), IL-17A$^+$ (D), T-bet$^+$ (E), GATA3$^+$ (F) and RORγt$^+$ (G) CD8$^+$ T-cells in the aortas and spleens of apoE$^{-/-}$ mice stimulated for 3.5 hwith PMA and ionomycin. Cells were pre-gated on live, Thy1.2$^+$CD8$^+$ T-cells. Individual data points and mean ± SEM of n = 5 (A, B, D, E) or n = 4 (C, F, G) apoE$^{-/-}$ mice of 39 to 49 weeks old, data are representative of n = 3 independent experiments. Significance was determined by using an unpaired *t*-test (A, C, F, G) or a Mann-Whitney test (B, D, E). $^*p < 0.05$, $^{**}p < 0.01$, $^{***}p < 0.001$.

and a reduction in T-bet-expressing cells (7.3% vs. 25.1%, Fig. 2D). Moreover, both Tc0 and Tc17 produced low amounts of IFN-γ (4.5% and 4.9%, respectively, Fig. 2C), indicating that these cells do not display a Tc1 phenotype. We observed a low production of IL-5 by both subsets, although the Tc0 subset produced 3-fold more IL-5 compared to the Tc17 subset (2.4% vs. 0.8%, Fig. 2E). The percentage of GATA3$^+$cells was low in both groups and did not differ between the two subsets (Fig. 2F), indicating the cultured cells do not display a Tc2 phenotype.

3.3. Adoptively transferred Tc17 cells migrate to the atherosclerotic lesion and affect the local CD4$^+$ T-cell population

To determine the effect of Tc17 cells on the development of atherosclerotic lesions, we performed an adoptive transfer of cultured Tc17 cells in LDLr$^{-/-}$ mice that were also deficient in CD8 and therefore had no endogenous CD8$^+$ T-cell population. The control group received a transfer of undifferentiated Tc0 cells. The adoptive transfer resulted in an increase in the CD8$^+$ T-cell population in the blood of both treatment groups over time (Fig. 3A). At four weeks post the first adoptive transfer, the circulating CD8$^+$ T-cells in the Tc17-treated group showed a substantially (4-fold) increased production of IL-



Figure 2: Tc0 and Tc17 cells demonstrate phenotypical differences in cytokine production and transcription factor expression. Flow cytometric analysis of IL-17A$^+$ (A), RORγt$^+$ (B), IFN-γ$^+$ (C), T-bet$^+$ (D), IL-5$^+$ (E) and GATA3$^+$ (F) CD8$^+$ T-cells isolated from C57Bl/6 mice and polarized for 3 days towards Tc0 or Tc17 cells. Cells were stimulated for 3.5 h with PMA and ionomycin and pre-gated on live, Thy1.2$^+$CD8$^+$ T-cells. Individual data points and mean ± SEM of n = 3, representative of n = 3 experiments. Significance was determined by using an unpaired *t*-test. *p < 0.05, **p < 0.01, ***p < 0.001.

17A compared to those in the Tc0-treated group (6.4% vs 1.7%, Fig. 3B), suggesting a stable Tc17 phenotype. Interestingly, we observed plasticity in the Tc0 subset, as these cells showed an increase in IFN-γ production from 4.5% at baseline to 53.6% four weeks after the first transfer. The Tc17 cells also showed an increased IFN-γ production from 4.9% to 44.9% (Fig. 2C, Fig. 3C). Therefore, we analyzed the relative amount of splenic IFN-γ+CD8$^+$ T-cells at sacrifice. Again, we observed that in the Tc0-treated group a large fraction of the cells produce IFN-γ (75.9%) compared to those in the Tc17-treated group (30.5%, Fig. 4A), although in both groups the percentage of IFN-γ$^+$cells were are notably higher than directly after *in vitro* differentiation (Fig. 2C). In line with our expectations, the Tc17-treated group still displayed more IL-17A$^+$cells as compared to the Tc0 group (7.6% vs 2.2%, Fig. 4B), albeit less compared to the *in vitro* cytokine production levels at the moment of injection (Fig. 2A). Moreover, at sacrifice, 86.1% of CD8$^+$ T-cells in the Tc0 group expressed T-bet, whereas in the Tc17 group this comprised 46.1% of the total CD8$^+$ population (Fig. 4C), suggesting the majority of the injected Tc0 cells had converted to a Tc1 phenotype. We observed a non-significant 1.2-fold increase in RORγt expression in the Tc17-treated group compared to the controls (Fig. 4D). Of note, the adoptively transferred CD8$^+$ T-cells were able to proliferate *in vivo*, as we observed 30.2% and 20.0% Ki-67 expression in the Tc0 and Tc17 group, respectively (Fig. 4E). Besides the spleen and blood, we were able to detect CD8$^+$ T-cells in the aortic lesions of both Tc0- and Tc17-recipient mice at the time of sacrifice (Fig. 4F), illustrating that



Figure 3: CD8$^+$ T-cell populations increase over time upon adoptive transfer in both treatment groups. (A) Analysis of percentages of CD8$^+$ T-cells in the blood of the CD8$^{-/-}$LDLr$^{-/-}$ mice after 2 and 4 injections of Tc0 or Tc17 cells and at sacrifice. Cells were pre-gated on live, Thy1.2$^+$cells, mean ± SEM. (B) IL-17A and (C) IFN-γ production by the CD8$^+$ T-cells in the blood after 4 injections, as analyzed by flow cytometry. Cells were stimulated for 3.5 h with PMA and ionomycin and pre-gated on live, Thy1.2$^+$CD8$^+$ T-cells. Individual data points and mean ± SEM, n = 9 mice per group. Significance was determined by using a two-way ANOVA with Bonferroni's multiple comparisons (A) or by using an unpaired *t*-test (B, C). $^*p < 0.05$, $^{**}p < 0.01$, $^{***}p < 0.001$.

the adoptively transferred CD8$^+$ T-cells migrate into the plaques. However, as the total number of lymphocytes within murine aortas is low, these numbers did not allow us to distinguish the different CD8$^+$ T-cell subsets. Interestingly, we did observe changes in the CD4$^+$ T-cell compartment in the lesion, showing a trend towards decreased IFN-γ production (20.9% vs 13.7%, P = 0.11, Fig. 4G), as well as a significant decrease in T-bet expression (9.4% vs 4.7%, Fig. 4H) in the Tc17-treated group, suggesting a skewing away from the inflammatory Th1 phenotype.

3.4. Adoptive transfer of Tc17 cells reduces atherosclerotic lesion development compared to Tc0 transfer in CD8-deficient atherosclerotic mice

We next assessed how the adoptive transfer affected atherosclerosis development. The weight of the mice and the plasma cholesterol levels were similar between both groups (Fig. S2). Plaque size was assessed in the aortic root lesions of the hearts. Interestingly, neutral lipid staining of the lesions revealed a 38% smaller lesion size in the mice that received the adoptively transferred Tc17 cells compared to those that received the Tc0 cells (Fig. 5A). The reduction in lesion size is most likely due to a decrease in total macrophage accumulation, as the absolute MOMA-positive area was decreased 2.2-fold in the Tc17-treated group (Fig. 5B). The relative plaque composition appeared to be similar in the Tc17- and Tc0-treated groups, as no change in the percentage of MOMA positive or collagen positive area was observed (Fig. 5B, C). Analysis of the VCAM-1$^+$area in the caps of the lesion revealed a 1.5-fold reduction in the Tc17-treated group, although this did not reach significance (P = 0.21, Fig. 5D). No differences were observed in both absolute and relative necrotic areas in the lesions between the two groups (Fig. S3).



Figure 4: Adoptive transfer of Tc17 cells in CD8$^{-/-}$LDLr$^{-/-}$ mice skews the CD4$^+$ T-cells towards a less inflammatory phenotype in the aortic microenvironment. Flow cytometric analysis of IFN-γ^+ (A), IL-17A$^+$ (B) T-bet$^+$ (C) RORγt$^+$ (D), and Ki-67$^+$ (E) CD8$^+$ T-cells in the spleens of the CD8$^{-/-}$LDLr$^{-/-}$ mice that received the adoptive transfer of Tc0 or Tc17 cells at the time of sacrifice. Cells were pre-gated on live, Thy1.2$^+$CD8$^+$ T-cells. (F) percentages of CD8$^+$ T-cells in the aortas of the CD8$^{-/-}$LDLr$^{-/-}$ mice at the time of sacrifice, analyzed by flow cytometry. Cells were pre-gated on live, Thy1.2$^+$cells. Flow cytometry analysis of IFN-γ^+ (G) and T-bet$^+$ (H) CD4$^+$ T-cells in the aortas of the CD8$^{-/-}$LDLr$^{-/-}$ mice at the time of sacrifice. Cells were pre-gated on live, Thy1.2$^+$CD4$^+$ T-cells. Individual data points and mean ± SEM, n = 9 mice per group. Cells were stimulated for 3.5 h with PMA and ionomycin. Significance was determined by using a Mann-Whitney test (A, B, D, G) or by using an unpaired *t*-test (C, E, F, H, I). $^*p < 0.05$, $^{**}p < 0.01$, $^{***}p < 0.001$.

4. Discussion

CD8$^+$ T-cells play an important role in the adaptive immune response, responding to intracellular pathogens. Recently, CD8$^+$ T-cell subsets such as Tc1, Tc2, and Tc17, which are characterized by their cytokine production resulting from different environmental cues, have been reported to also play a role in various autoimmune disorders [21]. We report a large increase in Tc17 cells in the atherosclerotic lesion microenvironment specifically and show that adoptive transfer of Tc17 cells results in a reduced atherosclerosis development compared to adoptive transfer of undifferentiated Tc0 cells, which differentiate into IFN-γ-producing Tc1 cells *in vivo.*

It is of particular interest to investigate the phenotype and function of CD8$^+$ T-cells within the lesion, as we have previously reported that CD8$^+$ T-cells can locally affect the lesion development and composition [43]. However, it is difficult to determine the presence of the different CD8$^+$ T-cell subsets within the lesional microenvironment based on their cytokine production, as the production of inflammatory cytokines produced by CD8$^+$ T-cells within the lesions is reduced [40]. Indeed, here we report a reduced percentage of IFN-γ^+lesion-derived CD8$^+$ T-cells compared to their counterparts in the



Figure 5: Adoptive transfer of Tc17 cells results in a decrease in lesion size, absolute collagen content and absolute macrophage content compared to the transfer of Tc0 cells in CD8$^{-/-}$LDLr$^{-/-}$ mice. (A) Quantification of lesion size in the aortic roots by Oil-red O staining and representative pictures of the lesions in CD8$^{-/-}$LDLr$^{-/-}$ mice treated with Tc0 or Tc17 cells. (B) Quantification of absolute and relative monocyte/macrophage content in the aortic root lesions by MOMA staining and representative pictures of the lesions. (C) Quantification of absolute and relative collagen content in the aortic root lesions by Sirius Red staining and representative pictures of the lesions. (D) Quantification of absolute VCAM-1^{+}area in the caps of the aortic root lesions by VCAM-1 staining and representative pictures of the lesions. Individual data points and mean ± SEM, n = 9 mice per group. Significance was determined by using a Mann-Whitney test (A, B) or by using an unpaired *t*-test (B, C, D). $^{*}p < 0.05$, $^{**}p < 0.01$, $^{***}p < 0.001$.

spleen and were hardly able to detect any IL-4, IL-5 or IL-17A production above background levels in the aorta of old apoE$^{-/-}$ mice. Therefore, we set out to measure the transcription factors associated with the Tc1, Tc2 and Tc17 subsets instead. There is

a reduced percentage of $CD8^+$ T-cells expressing T-bet in aortic lesions compared to splenic $CD8^+$ T-cells, suggesting that the pro-inflammatory Tc1 subset is not enriched in the lesion environment. However, we observed a modest increase in the percentage of cells expressing GATA3 in the lesions, implying an increase in Tc2 cells compared to lymphoid tissues. Strikingly, the percentage of cells expressing RORγt was strongly increased within the lesion microenvironment, which indicates a relative enrichment of Tc17 cells at the site of disease. It has previously been reported that 3 months of high-fat diet feeding in $apoE^{-/-}$ mice results in increased IL-17A production by splenic T-cells [44], although the cell-type responsible for this increase was not specifically identified. We observed only very low percentages of IL-17+$CD8^+$ T-cells in the spleens of $apoE^{-/-}$ mice, which were kept on a chow diet. Nonetheless, this study suggests that the inflammatory stimuli associated with the development of atherosclerosis may drive Tc17 skewing. Moreover, another analysis of the entire T-cell compartment showed an increase in IL-17A production in the aorta compared to the spleens of $apoE^{-/-}$ mice fed a WTD for 15 weeks [16]. As there are enhanced levels of the Tc17-polarizing cytokines IL-1β and IL-6 in the plaque [45, 46], the atherosclerotic environment in the lesion may indeed drive the local T-cells to differentiate towards a Tc17 phenotype, or stimulate increased recruitment of these cells.

In vitro polarization of isolated $CD8^+$ T-cells from wild-type mice resulted in successful differentiation towards a Tc17 phenotype, as described previously using a similar differentiation protocol [41]. Some basal levels of IFN-γ were produced by both the Tc0 and Tc17 cells, which is in agreement with available data [33, 41]. There was an increased expression of T-bet in the Tc0 subset compared to the Tc17 subset, which we hypothesize is due to the natural tendency of $CD8^+$ T-cells to differentiate towards an inflammatory effector phenotype upon the addition of IL-2, anti-CD3 and anti-CD28 antibodies [47]. Indeed, we found that the addition of anti-IFN-γ to the Tc0 conditions induced a great reduction in the T-bet expression, strengthening this hypothesis. However, upon adoptive transfer, Tc0 cells upregulated their expression of T-bet and IFN-γ production, indicating a switch towards the Tc1 phenotype. The Tc17 cells retained IL-17A production *in vivo*, though at lower levels than after *in vitro* differentiation. Moreover, they also increased their IFN-γ production, although significantly less pronounced than the Tc0 cells. Finally, the RORγt expression was downregulated in these cells. Indeed, previous work using antigen-specific Tc17 cells has shown that these cells can convert to IFN-γ-producing cells, although they retain some of their IL-17A production [41]. Similar plasticity has been reported for $CD4^+$ Th17 subsets [48, 49]. To date, the molecular mechanisms underlying these switches in phenotype remain unknown. However, the pro-inflammatory environment in the atherosclerotic mouse model may contribute to the increased production of IFN-γ, as hypercholesterolemia results in increased inflammatory responses [50, 51]. As $CD8^+$ T-cells activated by using anti-CD3 and CD28 antibodies tend to differentiate towards an effector phenotype [47, 52], it is likely that absence of anti-IFN-γ, that was present *in vitro*, as well as the systemic inflammatory signaling induced by the WTD-feeding in our mouse model, drives the switch towards a Tc1 phenotype. Indeed, the Tc0 cells showed a similar phenotype *in vivo* to that which we observed for the splenic $CD8^+$ T-cells in the atherosclerotic $apoE^{-/-}$ mice. Tc17 cells appeared more resistant to a Tc1 shift but still gained the ability to produce IFN-

γ. This may be explained by different transcriptional programs that are at work within this subset. IL-12, a cytokine known to be upregulated in atherosclerotic mice [53], is able to induce repressive epigenetic modification of the SOCS3 promoter. As SOCS3 is an essential mediator of IL-17 production, IL-12 can stimulate the conversion of Tc17 cells towards a mixed Tc1/Tc17 phenotype, associated with an increased IFN-γ production [54]. This is in agreement with our work, in which we observed maintenance of the Tc17 cytokine profile, but additional acquired characteristics of Tc1 cells. Of note, the Tc0 cells were more proliferative than their Tc17 counterparts. Possibly, the Tc0 cells resemble a more naïve phenotype as they are less fixed in their transcriptional program towards a certain phenotype. This enables them to proliferate more vigorously upon antigen recognition *in vivo*, compared to their more differentiated counterparts [55].

The injected CD8$^+$ T-cells were able to infiltrate the lesions *in vivo*, supporting the notion that at least part of the differences in the lesions observed between the Tc17- and Tc0-treated groups are due to local CD8$^+$ T-cell interactions. The Tc17-treated group showed a reduced plaque size compared to the Tc0-treated group. This suggests that the Tc17 cells could exert an atheroprotective effect, compared to the Tc0/Tc1 cells described here. Tc17 cells have been reported to have an impaired cytolytic function [32], however, we have previously shown a protective function for Fas ligand-induced cell death by CD8$^+$ T-cells [43], making a reduced cytolytic activity an unlikely explanation for the results observed here. There are reports suggesting a protective role for IL-17 in atherosclerosis. Increased IL-17 production reduced lesion development and neutralization of IL-17 accelerated atherosclerosis [18]. This protective effect is mediated by limiting inflammatory macrophage functions and reduced VCAM-1-mediated inflammatory cell recruitment towards the lesion. In agreement with this, we also observed a trend towards reduced VCAM-1 expression associated with a decrease in absolute macrophage content in the Tc17 treated group. This suggests that the protective effects of the Tc17 cells we observed here could be mediated through the increased IL-17A production.

Additionally, as the Tc0 cells produced more IFN-γ compared to the Tc17 cells, the differences in atherosclerotic lesion development could also result from the inflammatory effects of IFN-γ. IFN-γ is able to augment macrophage activation [56], which may, in turn, contribute to increased atherosclerosis development. IFN-$\gamma^{-/-}$apoE$^{-/-}$ mice have been shown to display a large reduction in atherosclerosis compared to controls, associated with a decrease in lesion cellularity but an increase in lesional collagen content [36]. In another study, administration of IFN-γ to apoE$^{-/-}$ mice resulted in a two-fold increase in lesion size, mediated by an increase in both T-cells as well as APCs [57]. CD8$^+$ T-cell-derived IFN-γ has previously been shown to have limited impact on lesion size and stability [58], but this study was performed in lymphocyte-deficient apoE$^{-/-}$ mice, which may overlook the effect of CD8$^+$ T-cell-derived IFN-γ on CD4$^+$ T-cells. We observed an increase in the total macrophage content of the lesions in the Tc0 group compared to the Tc17 group, which could be mediated by the increased IFN-γ that is produced in these mice. In fact, we observed an increase in T-bet expressing Th1 CD4$^+$ T-cells in the lesion microenvironment of the Tc0-treated mice. IFN-γ is an important regulator of T-bet expression within CD4$^+$ T-cells [59–61], suggesting that the increase

in Th1 cell population within the lesions of the Tc0-treated mice could be due to the increase in IFN-γ levels. In addition to the inflammatory effects of the adoptively transferred cells, this increase in the Th1 cell population within the lesions further promotes inflammation and atherogenesis, as these cells also display atherogenic functions [6]. Thus, both the increase in IL-17A as well as the decrease in IFN-γ production by the Tc17 cells compared to the Tc0 cells may have contributed to the protective effects observed here.

5. Conclusion

In conclusion, we have shown an enrichment of Tc17 cells in the plaque microenvironment of atherosclerotic mice. Adoptive transfer of Tc17 cells leads to a decrease in lesion size and is accompanied by a decrease in the Th1 cell population and reduced vascular inflammation compared to adoptive transfer of Tc0 cells. These findings demonstrate the presence of different Tc subsets within atherosclerotic lesions and warrant further research into the therapeutic options of skewing $CD8^+$ T-cell responses as a potential treatment for atherosclerosis.

Funding

This work was supported by the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation, Dutch Federation of University Medical Centres, the Netherlands Organisation for Health Research and Development, and the Royal Netherlands Academy of Sciences for the GENIUS project "Generating the best evidence-based pharmaceutical targets for atherosclerosis" [CVON2011-19].

Acknowledgments

We thank Servier for the free-of-charge use of their Medical Art images which can be found on https://smart.servier.com/

References

[1] R. A. van Dijk, A. J. F. Duinisveld, A. F. Schaapherder, A. Mulder-Stapel, J. F. Hamming, J. Kuiper, O. J. de Boer, A. C. van der Wal, F. D. Kolodgie, R. Virmani, and J. H. N. Lindeman, *A change in inflammatory footprint precedes plaque instability: A systematic evaluation of cellular aspects of the adaptive immune response in human atherosclerosis,* Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease **4**, e001403 (2015).

[2] S. A. Huber, P. Sakkinen, C. David, M. K. Newell, and R. P. Tracy, *T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia,* Circulation **103**, 2610 (2001).

[3] J. Khallou-Laschet, G. Caligiuri, E. Groyer, E. Tupin, A.-T. Gaston, B. Poirier, M. Kronenberg, L. Cohen José, D. Klatzmann, V. Kaveri Srini, and A. Nicoletti, *The proatherogenic role of T cells requires cell division and is dependent on the stage of the disease,* Arteriosclerosis, Thrombosis, and Vascular Biology **26**, 353 (2006).

[4] A. K. Robertson and G. K. Hansson, *T cells in atherogenesis: for better or for worse?* Arterioscler Thromb Vasc Biol **26**, 2421 (2006).

[5] C. Grönberg, J. Nilsson, and M. Wigren, *Recent advances on CD4^{+} T cells in atherosclerosis and its implications for therapy,* European Journal of Pharmacology **816**, 58 (2017).

[6] C. Buono, C. J. Binder, G. Stavrakis, J. L. Witztum, L. H. Glimcher, and A. H. Lichtman, *T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses,* Proc Natl Acad Sci U S A **102**, 1596 (2005).

[7] J. Frostegard, A. K. Ulfgren, P. Nyberg, U. Hedin, J. Swedenborg, U. Andersson, and G. K. Hansson, *Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines,* Atherosclerosis **145**, 33 (1999).

[8] H. Ait-Oufella, B. L. Salomon, S. Potteaux, A. K. Robertson, P. Gourdy, J. Zoll, R. Merval, B. Esposito, J. L. Cohen, S. Fisson, R. A. Flavell, G. K. Hansson, D. Klatzmann, A. Tedgui, and Z. Mallat, *Natural regulatory T cells control the development of atherosclerosis in mice,* Nat Med **12**, 178 (2006).

[9] G. H. van Puijvelde, A. D. Hauer, P. de Vos, R. van den Heuvel, M. J. van Herwijnen, R. van der Zee, W. van Eden, T. J. van Berkel, and J. Kuiper, *Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis,* Circulation **114**, 1968 (2006).

[10] C. J. Binder, K. Hartvigsen, M.-K. Chang, M. Miller, D. Broide, W. Palinski, L. K. Curtiss, M. Corr, and J. L. Witztum, *IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis,* The Journal of clinical investigation **114**, 427 (2004).

[11] A. M. Miller, D. Xu, D. L. Asquith, L. Denby, Y. Li, N. Sattar, A. H. Baker, I. B. McInnes, and F. Y. Liew, *IL-33 reduces the development of atherosclerosis,* The Journal of experimental medicine **205**, 339 (2008).

[12] V. L. King, S. J. Szilvassy, and A. Daugherty, *Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor$^{-/-}$ mice,* Arterioscler Thromb Vasc Biol **22**, 456 (2002).

[13] P. Davenport and P. G. Tipping, *The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice,* Am J Pathol **163**, 1117 (2003).

[14] A. C. Foks, G. H. van Puijvelde, I. Bot, M. N. ter Borg, K. L. Habets, J. L. Johnson, H. Yagita, T. J. van Berkel, and J. Kuiper, *Interruption of the OX40-OX40 ligand pathway in LDL receptor-deficient mice causes regression of atherosclerosis,* J Immunol **191**, 4573 (2013).

[15] C. Erbel, L. Chen, F. Bea, S. Wangler, S. Celik, F. Lasitschka, Y. Wang, D. Bockler, H. A. Katus, and T. J. Dengler, *Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice,* J Immunol **183**, 8167 (2009).

[16] E. Smith, K. M. Prasad, M. Butcher, A. Dobrian, J. K. Kolls, K. Ley, and E. Galkina, *Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice,* Circulation **121**, 1746 (2010).

[17] T. van Es, G. H. van Puijvelde, O. H. Ramos, F. M. Segers, L. A. Joosten, W. B. van den Berg, I. M. Michon, P. de Vos, T. J. van Berkel, and J. Kuiper, *Attenuated atherosclerosis upon IL-17R signaling disruption in ldlr deficient mice,* Biochem Biophys Res Commun **388**, 261 (2009).

[18] S. Taleb, M. Romain, B. Ramkhelawon, C. Uyttenhove, G. Pasterkamp, O. Herbin, B. Esposito, N. Perez, H. Yasukawa, J. Van Snick, A. Yoshimura, A. Tedgui, and Z. Mallat, *Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis,* J Exp Med **206**, 2067 (2009).

[19] N. S. Joshi, W. Cui, A. Chandele, H. K. Lee, D. R. Urso, J. Hagman, L. Gapin, and S. M. Kaech, *Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of t-bet transcription factor,* Immunity **27**, 281 (2007).

[20] M. E. Pipkin, J. A. Sacks, F. Cruz-Guilloty, M. G. Lichtenheld, M. J. Bevan, and A. Rao, *Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells,* Immunity **32**, 79 (2010).

[21] H. W. Mittrucker, A. Visekruna, and M. Huber, *Heterogeneity in the differentiation and function of CD8(+) T cells,* Arch Immunol Ther Exp (Warsz) **62**, 449 (2014).

[22] M. Grange, G. Verdeil, F. Arnoux, A. Griffon, S. Spicuglia, J. Maurizio, M. Buferne, A. M. Schmitt-Verhulst, and N. Auphan-Anezin, *Active stat5 regulates t-bet and eomesodermin expression in CD8 T cells and imprints a t-bet-dependent Tc1 program with repressed IL-6/TGF-beta1 signaling,* J Immunol **191**, 3712 (2013).

[23] B. Wizel, M. Nunes, and R. L. Tarleton, *Identification of trypanosoma cruzi trans-sialidase family members as targets of protective CD8+ TC1 responses,* J Immunol **159**, 6120 (1997).

[24] H. Hamada, E. Bassity, A. Flies, T. M. Strutt, L. Garcia-Hernandez Mde, K. K. McKinstry, T. Zou, S. L. Swain, and R. W. Dutton, *Multiple redundant effector mechanisms of CD8+ T cells protect against influenza infection,* J Immunol **190**, 296 (2013).

[25] R. A. Kemp and F. Ronchese, *Tumor-specific tc1, but not tc2, cells deliver protective antitumor immunity,* J Immunol **167**, 6497 (2001).

[26] M. Croft, L. Carter, S. L. Swain, and R. W. Dutton, *Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles,* J Exp Med **180**, 1715 (1994).

[27] M. Omori, M. Yamashita, M. Inami, M. Ukai-Tadenuma, M. Kimura, Y. Nigo, H. Hosokawa, A. Hasegawa, M. Taniguchi, and T. Nakayama, *CD8 T cell-specific downregulation of histone hyperacetylation and gene activation of the IL-4 gene locus by rog, repressor of gata,* Immunity **19**, 281 (2003).

[28] Y. Jia, J. Domenico, K. Takeda, J. Han, M. Wang, M. Armstrong, N. Reisdorph, B. P. O'Connor, J. J. Lucas, and E. W. Gelfand, *Steroidogenic enzyme Cyp11a1 regulates type 2 $CD8^+$ T cell skewing in allergic lung disease,* Proc Natl Acad Sci U S A **110**, 8152 (2013).

[29] F. Ning, K. Takeda, M. Schedel, J. Domenico, A. Joetham, and E. W. Gelfand, *Hypoxia enhances CD8(+) TC2 cell-dependent airway hyperresponsiveness and inflammation through hypoxia-inducible factor 1alpha,* J Allergy Clin Immunol **143**, 2026 (2019).

[30] B. Hilvering, T. S. C. Hinks, L. Stöger, E. Marchi, M. Salimi, R. Shrimanker, W. Liu, W. Chen, J. Luo, S. Go, T. Powell, J. Cane, S. Thulborn, A. Kurioka, T. Leng, J. Matthews, C. Connolly, C. Borg, M. Bafadhel, C. B. Willberg, A. Ramasamy, R. Djukanović, G. Ogg, I. D. Pavord, P. Klenerman, and L. Xue, *Type-2 $CD8^+$ T lymphocytes responsive to PGD2 and LTE4 in severe eosinophilic asthma,* bioRxiv , 247171 (2018).

[31] B. A. Cho, J. H. Sim, J. A. Park, H. W. Kim, W. H. Yoo, S. H. Lee, D. S. Lee, J. S. Kang, Y. I. Hwang, W. J. Lee, I. Kang, E. B. Lee, and H. R. Kim, *Characterization of effector memory $CD8^+$ T cells in the synovial fluid of rheumatoid arthritis,* J Clin Immunol **32**, 709 (2012).

[32] H. Hamada, M. d. l. L. Garcia-Hernandez, J. B. Reome, S. K. Misra, T. M. Strutt, K. K. McKinstry, A. M. Cooper, S. L. Swain, and R. W. Dutton, *Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge,* Journal of immunology **182**, 3469 (2009).

[33] M. Huber, S. Heink, H. Grothe, A. Guralnik, K. Reinhard, K. Elflein, T. Hunig, H. W. Mittrucker, A. Brustle, T. Kamradt, and M. Lohoff, *A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity,* Eur J Immunol **39**, 1716 (2009).

[34] A. Saxena, S. Desbois, N. Carrie, M. Lawand, L. T. Mars, and R. S. Liblau, *Tc17 CD8$^+$ T cells potentiate Th1-mediated autoimmune diabetes in a mouse model,* J Immunol **189**, 3140 (2012).

[35] B. Menon, N. J. Gullick, G. J. Walter, M. Rajasekhar, T. Garrood, H. G. Evans, L. S. Taams, and B. W. Kirkham, *Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression,* Arthritis Rheumatol **66**, 1272 (2014).

[36] S. Gupta, A. M. Pablo, X. Jiang, N. Wang, A. R. Tall, and C. Schindler, *IFN-gamma potentiates atherosclerosis in apoE knock-out mice,* J Clin Invest **99**, 2752 (1997).

[37] C. Cochain, M. Koch, S. M. Chaudhari, M. Busch, J. Pelisek, L. Boon, and A. Zernecke, *CD8$^+$ T cells regulate monopoiesis and circulating Ly6C-high monocyte levels in atherosclerosis in mice,* Circ Res **117**, 244 (2015).

[38] T. T. P. Seijkens, K. Poels, S. Meiler, C. M. van Tiel, P. J. H. Kusters, M. Reiche, D. Atzler, H. Winkels, M. Tjwa, H. Poelman, B. Slutter, J. Kuiper, M. Gijbels, J. A. Kuivenhoven, L. P. Matic, G. Paulsson-Berne, U. Hedin, G. K. Hansson, G. A. F. Nicolaes, M. Daemen, C. Weber, N. Gerdes, M. P. J. de Winther, and E. Lutgens, *Deficiency of the T cell regulator Casitas B-cell lymphoma-B aggravates atherosclerosis by inducing CD8+ T cell-mediated macrophage death,* Eur Heart J **40**, 372 (2019).

[39] T. Ponnusamy, K. V. Srikanth, R. Manjunatha, V. V. Kakkar, and L. Mundkur, *Circulating Th17 and Tc17 cells and their imbalance with regulatory T cells is associated with myocardial infarction in young indian patients,* World Journal of Cardiovascular Diseases **5**, 373 (2015).

[40] J. van Duijn, M. van Elsas, N. Benne, M. Depuydt, A. Wezel, H. Smeets, I. Bot, W. Jiskoot, J. Kuiper, and B. Slütter, *CD39 identifies a microenvironment-specific anti-inflammatory CD8$^+$ T-cell population in atherosclerotic lesions,* Atherosclerosis **285**, 71 (2019).

[41] H. R. Yen, T. J. Harris, S. Wada, J. F. Grosso, D. Getnet, M. V. Goldberg, K. L. Liang, T. C. Bruno, K. J. Pyle, S. L. Chan, R. A. Anders, C. L. Trimble, A. J. Adler, T. Y. Lin, D. M. Pardoll, C. T. Huang, and C. G. Drake, *Tc17 CD8 T cells: functional plasticity and subset diversity,* J Immunol **183**, 7161 (2009).

[42] M. D. Lewis, E. de Leenheer, S. Fishman, L. K. Siew, G. Gross, and F. S. Wong, *A reproducible method for the expansion of mouse CD8+ T lymphocytes,* J Immunol Methods **417**, 134 (2015).

[43] J. van Duijn, E. Kritikou, N. Benne, T. van der Heijden, G. H. van Puijvelde, M. J. Kroner, F. H. Schaftenaar, A. C. Foks, A. Wezel, H. Smeets, H. Yagita, I. Bot, W. Jiskoot, J. Kuiper, and B. Slutter, *CD8+ T-cells contribute to lesion stabilization in*

advanced atherosclerosis by limiting macrophage content and CD4 T-cell responses, Cardiovasc Res **115**, 729 (2019).

[44] M. S. Madhur, S. A. Funt, L. Li, A. Vinh, W. Chen, H. E. Lob, Y. Iwakura, Y. Blinder, A. Rahman, A. A. Quyyumi, and D. G. Harrison, *Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein E-deficient mice,* Arterioscler Thromb Vasc Biol **31**, 1565 (2011).

[45] A. B. Reiss, N. M. Siegart, and J. D. Leon, *Interleukin-6 in atherosclerosis: atherogenic or atheroprotective?* Clinical Lipidology **12**, 14 (2017).

[46] P. Libby, *Interleukin-1 beta as a target for atherosclerosis therapy: Biological basis of cantos and beyond,* J Am Coll Cardiol **70**, 2278 (2017).

[47] D. P. Hughes, D. Baskar, F. F. Urban, M. S. Friedman, T. M. Braun, and K. T. McDonagh, *Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo,* Cytotherapy **7**, 396 (2005).

[48] Y. K. Lee, H. Turner, C. L. Maynard, J. R. Oliver, D. Chen, C. O. Elson, and C. T. Weaver, *Late developmental plasticity in the T helper 17 lineage,* Immunity **30**, 92 (2009).

[49] D. Bending, H. De la Pena, M. Veldhoen, J. M. Phillips, C. Uyttenhove, B. Stockinger, and A. Cooke, *Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice,* J Clin Invest **119**, 565 (2009).

[50] M. Centa, K. E. Prokopec, M. G. Garimella, K. Habir, L. Hofste, J. M. Stark, A. Dahdah, C. A. Tibbitt, K. A. Polyzos, A. Gistera, D. K. Johansson, N. N. Maeda, G. K. Hansson, D. F. J. Ketelhuth, J. M. Coquet, C. J. Binder, M. C. I. Karlsson, and S. Malin, *Acute loss of apolipoprotein E triggers an autoimmune response that accelerates atherosclerosis,* Arterioscler Thromb Vasc Biol **38**, e145 (2018).

[51] K. Y. Chyu, W. M. Lio, P. C. Dimayuga, J. Zhou, X. Zhao, J. Yano, P. Trinidad, T. Honjo, B. Cercek, and P. K. Shah, *Cholesterol lowering modulates T cell function in vivo and in vitro,* PLoS One **9**, e92095 (2014).

[52] B. Gunnlaugsdottir, S. M. Maggadottir, and B. R. Ludviksson, *Anti-CD28-induced co-stimulation and TCR avidity regulates the differential effect of TGF-beta1 on CD4+ and CD8+ naive human T-cells,* Int Immunol **17**, 35 (2005).

[53] T. S. Lee, H. C. Yen, C. C. Pan, and L. Y. Chau, *The role of interleukin 12 in the development of atherosclerosis in apoE-deficient mice,* Arterioscler Thromb Vasc Biol **19**, 734 (1999).

[54] T. Satoh, M. Tajima, D. Wakita, H. Kitamura, and T. Nishimura, *The development of IL-17/IFN-gamma-double producing CTLs from Tc17 cells is driven by epigenetic suppression of Socs3 gene promoter,* Eur J Immunol **42**, 2329 (2012).

[55] J. Geginat, A. Lanzavecchia, and F. Sallusto, *Proliferation and differentiation potential of human CD8^{+} memory T-cell subsets in response to antigen or homeostatic cytokines,* Blood **101**, 4260 (2003).

[56] T. K. Held, X. Weihua, L. Yuan, D. V. Kalvakolanu, and A. S. Cross, *Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor alpha and interleukin-1,* Infect Immun **67**, 206 (1999).

[57] S. C. Whitman, P. Ravisankar, H. Elam, and A. Daugherty, *Exogenous interferon-γ enhances atherosclerosis in apolipoprotein E$^{-/-}$ mice,* The American Journal of Pathology **157**, 1819 (2000).

[58] T. Kyaw, A. Winship, C. Tay, P. Kanellakis, H. Hosseini, A. Cao, P. Li, P. Tipping, A. Bobik, and B. H. Toh, *Cytotoxic and proinflammatory CD8^{+} T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice,* Circulation **127**, 1028 (2013).

[59] A. A. Lighvani, D. M. Frucht, D. Jankovic, H. Yamane, J. Aliberti, B. D. Hissong, B. V. Nguyen, M. Gadina, A. Sher, W. E. Paul, and J. J. O'Shea, *T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells,* Proc Natl Acad Sci U S A **98**, 15137 (2001).

[60] A. Cope, G. Le Friec, J. Cardone, and C. Kemper, *The Th1 life cycle: molecular control of IFN-gamma to IL-10 switching,* Trends Immunol **32**, 278 (2011).

[61] R. B. Smeltz, J. Chen, R. Ehrhardt, and E. M. Shevach, *Role of IFN-gamma in Th1 differentiation: IFN-gamma regulates IL-18R alpha expression by preventing the negative effects of IL-4 and by inducing/maintaining IL-12 receptor beta 2 expression,* J Immunol **168**, 6165 (2002).

Supplementary information



Figure S1: IFN-γ production in murine atherosclerotic lesions is restricted to T-bet-expressing CD8$^+$ T-cells. Flow cytometric analysis of IFN-γ production by T-bet+, GATA3$^+$ and RORγt$^+$ CD8$^+$ T-cells in the aortas of apoE$^{-/-}$ mice stimulated for 3.5 hwith PMA and ionomycin. Cells were pre-gated on live, Thy1.2$^+$CD8$^+$ T-cells and the indicated transcription factors. Individual data points and mean ± SEM of n = 4 apoE$^{-/-}$ mice that were 46 to 49 weeks old. Significance was determined by using a one-way ANOVA with Bonferroni's multiple comparisons. $^*p < 0.05$, $^{**}p < 0.01$.



Figure S2: Adoptive transfer of Tc0 or Tc17 cells into CD8$^{-/-}$LDLr$^{-/-}$ mice does not result in any significant differences in weight or serum cholesterol. (A) Body weights of CD8$^{-/-}$LDLr$^{-/-}$ mice that received adoptive transfer of Tc0 or Tc17 cells once weekly, mean ± SEM. Significance was determined by using a two-way ANOVA with Bonferroni's multiple comparisons (B) Serum cholesterol levels at sacrifice. Individual data points and mean ± SEM, n = 9 mice per group. Significance was determined by using an unpaired *t*-test.



Figure S3: Adoptive transfer of Tc0 or Tc17 cells into CD8$^{-/-}$LDLr$^{-/-}$ mice does not change absolute or relative necrotic areas in the lesions. Quantification of absolute and relative necrotic core content by Masson's Trichrome staining in the aortic root lesions of CD8$^{-/-}$LDLr$^{-/-}$ mice treated with Tc0 or Tc17 cells. Individual data points and mean ± SEM, n = 9 mice per group. The data was tested for significance by using unpaired *t*-tests.

Table S1: Antibodies used for flow cytometric analysis.

Antibody	Fluorochrome	Clone	Supplier
CD4	APC	GK1.5	GK1.5
CD4	PerCP	RM4-5	BD Biosciences
CD4	V500	RM4-5	BD Biosciences
CD8	eFluor450	53-6.7	eBioscience
CD8	FITC	53-6.7	eBioscience
CD8	PE-Texas Red	5H10	Invitrogen
EOMES	APC	Dan11mag	eBioscience
GATA3	PE	16E10A23	eBioscience
IFN-γ	eFluor450	XMG1.2	eBioscience
IL-17A	PE	TC11-18H10.1	Biolegend
IL-17A	PEdazzle594	TC11-18H10.1	Biolegend
IL-5	APC	TRFK5	Biolegend
Ki-67	FITC	SolA15	eBioscience
RORyt	BV650	Q31-378	BD Biosciences
Thy1.2	PeCy7	53-2.1	Biolegend
Thy1.2	PerCP-cy5.5	53-2.1	Biolegend
T-bet	PeCy7	eBio4B10	eBioscience
Fixable Viability	Efluor780	-	eBioscience